Skin Tape Harvesting for Transcriptomics Analysis

Inclusion Criteria:

1. Male or female between ages of 18 to 75 years

2. Psoriasis Group Only: Clinical diagnosis of moderate to severe plaque psoriasis at
least 6 months prior to enrollment with a PASI equal to 5 or greater and PGA 3-4;

3. Psoriasis Group Only: Have lesional and non-lesional skin appropriate for biopsy which
has not been treated with topical therapies 2 weeks prior to biopsy collection;

4. Psoriasis Group Only: Lesional skin for biopsy must have a Target Lesion Severity
Score equal to 6 or greater;

5. Psoriasis Group Only: If subject was on biologic therapy, lesion to be biopsied should
have minimal response to therapy;

6. Psoriasis Group Only: Psoriatic plaque lesion for biopsy on skin areas typically
affected by psoriasis and representative of overall disease severity;

7. Healthy controls will have neither history of skin diseases nor current evidence of
other active inflammatory skin disease.

Exclusion Criteria:

1. Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis,
medication-induced or medication-exacerbated psoriasis, or new onset guttate
psoriasis.

2. Evidence of skin conditions other than psoriasis that would interfere with the
evaluations.

3. Use of systemic anti-psoriasis therapies within 28 days of study initiation, or three
times the half-life of the drug, whichever is longer;

4. Use of UVB therapy or moderate strength non-steroidal topical treatments on lesion to
be biopsied within 14 days of study initiation;

5. Current enrollment in investigational device or investigational drug trial(s), or
receipt of any investigational agent(s) within 28 days before baseline visit;

6. Use of JAK inhibitor within 4 weeks of screening;

7. Known HIV-positive status or known history of any other immuno-suppressing disease;

8. Exposure to hepatitis B or hepatitis C or to high risk factors for hepatitis B or C,
such as intravenous drug use in patient;

9. Pregnant or nursing females;

10. Subjects with a history of keloid formation or hypertrophic scarring;

11. Individuals who have lidocaine sensitivity.